Silo Pharma Inc (SILO)

$0.67 +0.01 (0.89%)
Market Cap 2.99M
Revenue (ttm) 70,000.00
Net Income (ttm) -4.39M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -6,271.43%
Debt to Equity Ratio 0.00
Volume 199,700
Avg Vol 1,278,908
Day's Range N/A - N/A
Shares Out 4.48M
Stochastic %K 66%
Beta 0.29
Analysts Strong Sell
Price Target $10.00

Company Profile

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders....

Industry: Biotechnology
Sector: Healthcare
Phone: 718 400 9031
Address:
677 North Washington Boulevard, Sarasota, United States
KhalidsCapital
KhalidsCapital Jul. 25 at 12:55 AM
TGL is quietly building one of the most explosive setups in small caps. Catalysts, tiny float, big move written all over it • AI + blockchain convergence • 2.7M+ user reach • Launching new AI platform this quarter • Tight float • Market cap still under the radar I’ve seen this movie before… and the ending is 🔥 $CLNV $HUBC $SILO $CYCC
2 · Reply
SlamminSammmy
SlamminSammmy Jul. 24 at 8:32 PM
$SILO she is about ready to blow! 🚀🚀
0 · Reply
aperzy20
aperzy20 Jul. 24 at 12:18 PM
$SILO come on baby!!!! lets gooo big money here
0 · Reply
Arodrcp
Arodrcp Jul. 23 at 11:14 PM
$SILO what do you think, we getting ready for blast off?
1 · Reply
aperzy20
aperzy20 Jul. 23 at 6:29 PM
$SILO lets gooo!!!!!!
0 · Reply
DollaBillsYo
DollaBillsYo Jul. 23 at 6:15 PM
$SILO alittle action today.
0 · Reply
Arodrcp
Arodrcp Jul. 23 at 5:09 PM
$SILO waking up!
1 · Reply
levans80
levans80 Jul. 23 at 2:31 AM
$HCTI $IXHL $NRSN $PSTV $SILO
0 · Reply
JL_TradeZ
JL_TradeZ Jul. 23 at 2:31 AM
🚨Biotech Watchlist July 23rd $IXHL: FDA-cleared Phase 3, float rotated, no dilution $NRSN: ALS trial success, insider owned, chart is pressing breakout $SILO: PTSD program + obesity drug, no debt, 6.1M float APLM: Float under 1M, $8.86 cash/share, China approval $PSTV: REYOBIQ™ updates + clean chart under 0.44 Bonus Play $HCTI: AI-health crossover play with a coil breakout and 10x volume surge. Float is large but acting like a micro. Could ignite if sector momentum carries over Biotech momentum is back after ABVX ripped from $10 to $57 AH on Phase 3 data. These setups all have real catalysts and breakout potential. Don’t force anything. Let the charts confirm and the volume tell you where to size in.
4 · Reply
aperzy20
aperzy20 Jul. 22 at 6:47 PM
$SILO
0 · Reply
Latest News on SILO
Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15

Jul 16, 2025, 8:45 AM EDT - 12 days ago

Silo Pharma Announces Completion of Dosing in Safety Study of PTSD Drug SPC-15

Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025

Jul 7, 2025, 8:15 AM EDT - 21 days ago

Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 IND Submission with Pre-Clinical Study Data Expected in Q3 2025

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Jun 25, 2025, 8:38 AM EDT - 4 weeks ago

Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

Jun 25, 2025, 8:27 AM EDT - 4 weeks ago

Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease.

HOTH

Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears

Jun 11, 2025, 9:00 AM EDT - 6 weeks ago

Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears

Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

Jun 5, 2025, 9:15 AM EDT - 7 weeks ago

Silo Pharma Board of Directors Approves Purchase of Bitcoin as Treasury Reserve Asset

Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15

May 21, 2025, 8:55 AM EDT - 2 months ago

Silo Pharma Partners with Resyca for IND-Supporting Intranasal Drug-Device Study of PTSD Drug SPC-15

Silo Pharma Announces Closing of $2 Million Public Offering

May 16, 2025, 4:15 PM EDT - 2 months ago

Silo Pharma Announces Closing of $2 Million Public Offering

Silo Pharma Announces Pricing of $2 Million Public Offering

May 15, 2025, 9:15 AM EDT - 2 months ago

Silo Pharma Announces Pricing of $2 Million Public Offering

Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15

May 14, 2025, 4:07 PM EDT - 2 months ago

Silo Pharma Selects Veloxity Labs for Bioanalytical IND-Enabling Study for our Novel Intranasal PTSD Therapy, SPC-15

Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories

May 14, 2025, 8:40 AM EDT - 2 months ago

Silo Pharma Advances PTSD Drug SPC-15 Toward First-in-Human Trial with Key Safety Study Initiated at Frontage Laboratories

Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study

Apr 30, 2025, 8:11 AM EDT - 3 months ago

Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study

Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug

Apr 28, 2025, 7:50 AM EDT - 3 months ago

Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment

Mar 26, 2025, 8:40 AM EDT - 4 months ago

Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment

Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment

Feb 26, 2025, 1:30 PM EST - 5 months ago

Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment

Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment

Feb 18, 2025, 8:50 AM EST - 5 months ago

Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment

Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia

Feb 11, 2025, 7:45 AM EST - 5 months ago

Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia

Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment

Jan 22, 2025, 8:29 AM EST - 6 months ago

Silo Pharma Advances Intellectual Property Portfolio with Provisional Patent Filing for PTSD Treatment

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

Jan 2, 2025, 8:45 AM EST - 7 months ago

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

Dec 18, 2024, 7:35 AM EST - 7 months ago

Silo Pharma Initiates Pharmacokinetic and Tolerability Study for SP-26 Targeting Chronic Pain and Fibromyalgia

Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management

Nov 29, 2024, 8:05 AM EST - 8 months ago

Silo Pharma Enters Joint Development Agreement for SP-26 Ketamine Implant Device Targeting Pain Management

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

Nov 18, 2024, 8:40 AM EST - 9 months ago

Silo Pharma Announces Positive Results for Novel SPC-15 Treatment Targeting Stress-Related Disorders

Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant

Oct 31, 2024, 8:35 AM EDT - 9 months ago

Silo Pharma Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD

Sep 10, 2024, 6:35 AM EDT - 11 months ago

Silo Pharma Announces Completion of FDA Pre-IND Meeting to Advance Development of SPC-15 for Treatment of PTSD

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

Aug 14, 2024, 2:30 PM EDT - 1 year ago

Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic

Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide

Aug 7, 2024, 8:13 AM EDT - 1 year ago

Silo Pharma Announces Partnership with Global CRO for Central Nervous System Homing Peptide

Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference

Jul 26, 2024, 8:20 AM EDT - 1 year ago

Silo Pharma to Present at H.C. Wainwright Annual Global Investment Conference

Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jul 22, 2024, 4:45 PM EDT - 1 year ago

Silo Pharma Announces Closing of $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jul 19, 2024, 8:01 AM EDT - 1 year ago

Silo Pharma Announces $2.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Silo Pharma Finds Partner For Device Development for Intranasal PTSD Drug

Jul 18, 2024, 12:44 PM EDT - 1 year ago

Silo Pharma Finds Partner For Device Development for Intranasal PTSD Drug

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

Jul 18, 2024, 8:25 AM EDT - 1 year ago

Silo Pharma and Resyca BV Partner on Device and CMC Development for Intranasal PTSD Drug SPC-15

Why Is Nano-Cap Silo Pharma Stock Skyrocketing On Tuesday?

Jul 16, 2024, 10:50 AM EDT - 1 year ago

Why Is Nano-Cap Silo Pharma Stock Skyrocketing On Tuesday?

Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic

Jul 16, 2024, 6:30 AM EDT - 1 year ago

Silo Pharma Secures Exclusive Global License for Alzheimer's Therapeutic

Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety

Jun 26, 2024, 8:50 AM EDT - 1 year ago

Silo Pharma Partners with AmplifyBio to Advance SPC-15 for PTSD and Anxiety

Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia

Jun 7, 2024, 8:18 AM EDT - 1 year ago

Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for Fibromyalgia

Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jun 6, 2024, 4:50 PM EDT - 1 year ago

Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety

Jun 4, 2024, 8:41 AM EDT - 1 year ago

Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety

Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention

May 21, 2024, 8:45 AM EDT - 1 year ago

Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention

Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine

May 14, 2024, 8:45 AM EDT - 1 year ago

Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in Ketamine

Silo Pharma Announces Positive Results for Intranasal PTSD Treatment

Apr 23, 2024, 8:15 AM EDT - 1 year ago

Silo Pharma Announces Positive Results for Intranasal PTSD Treatment

Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease Therapeutic

Apr 10, 2024, 8:11 AM EDT - 1 year ago

Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer's Disease Therapeutic

Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain

Mar 18, 2024, 7:15 AM EDT - 1 year ago

Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain

Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD

Feb 28, 2024, 8:25 AM EST - 1 year ago

Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD

Silo Pharma's SP-26 Ketamine Implant Demonstrates Successful Drug Delivery

Feb 14, 2024, 8:45 AM EST - 1 year ago

Silo Pharma's SP-26 Ketamine Implant Demonstrates Successful Drug Delivery

Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology

Feb 1, 2024, 10:00 AM EST - 1 year ago

Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology

Silo Pharma Announces Positive Results in Alzheimer's Disease Study

Jan 24, 2024, 8:55 AM EST - 1 year ago

Silo Pharma Announces Positive Results in Alzheimer's Disease Study

Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD

Jan 4, 2024, 8:55 AM EST - 1 year ago

Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD

Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia

Dec 28, 2023, 8:25 AM EST - 1 year ago

Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for Fibromyalgia

Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD

Nov 21, 2023, 8:01 AM EST - 1 year ago

Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD

Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD

Nov 8, 2023, 8:11 AM EST - 1 year ago

Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD

KhalidsCapital
KhalidsCapital Jul. 25 at 12:55 AM
TGL is quietly building one of the most explosive setups in small caps. Catalysts, tiny float, big move written all over it • AI + blockchain convergence • 2.7M+ user reach • Launching new AI platform this quarter • Tight float • Market cap still under the radar I’ve seen this movie before… and the ending is 🔥 $CLNV $HUBC $SILO $CYCC
2 · Reply
SlamminSammmy
SlamminSammmy Jul. 24 at 8:32 PM
$SILO she is about ready to blow! 🚀🚀
0 · Reply
aperzy20
aperzy20 Jul. 24 at 12:18 PM
$SILO come on baby!!!! lets gooo big money here
0 · Reply
Arodrcp
Arodrcp Jul. 23 at 11:14 PM
$SILO what do you think, we getting ready for blast off?
1 · Reply
aperzy20
aperzy20 Jul. 23 at 6:29 PM
$SILO lets gooo!!!!!!
0 · Reply
DollaBillsYo
DollaBillsYo Jul. 23 at 6:15 PM
$SILO alittle action today.
0 · Reply
Arodrcp
Arodrcp Jul. 23 at 5:09 PM
$SILO waking up!
1 · Reply
levans80
levans80 Jul. 23 at 2:31 AM
$HCTI $IXHL $NRSN $PSTV $SILO
0 · Reply
JL_TradeZ
JL_TradeZ Jul. 23 at 2:31 AM
🚨Biotech Watchlist July 23rd $IXHL: FDA-cleared Phase 3, float rotated, no dilution $NRSN: ALS trial success, insider owned, chart is pressing breakout $SILO: PTSD program + obesity drug, no debt, 6.1M float APLM: Float under 1M, $8.86 cash/share, China approval $PSTV: REYOBIQ™ updates + clean chart under 0.44 Bonus Play $HCTI: AI-health crossover play with a coil breakout and 10x volume surge. Float is large but acting like a micro. Could ignite if sector momentum carries over Biotech momentum is back after ABVX ripped from $10 to $57 AH on Phase 3 data. These setups all have real catalysts and breakout potential. Don’t force anything. Let the charts confirm and the volume tell you where to size in.
4 · Reply
aperzy20
aperzy20 Jul. 22 at 6:47 PM
$SILO
0 · Reply
Green_dillo
Green_dillo Jul. 17 at 8:56 PM
$SILO ⏰️💦
0 · Reply
BULLonROIDS
BULLonROIDS Jul. 17 at 7:07 PM
$SILO $1+ coming soon!!!!
0 · Reply
aperzy20
aperzy20 Jul. 17 at 1:48 PM
$SILO $XXII $VLCN
0 · Reply
aperzy20
aperzy20 Jul. 17 at 1:39 PM
$SILO
0 · Reply
ThebookofEli
ThebookofEli Jul. 17 at 1:25 AM
$SILO taking a bit here
0 · Reply
dogood
dogood Jul. 16 at 10:54 PM
$SILO open is also moving
0 · Reply
dogood
dogood Jul. 16 at 10:46 PM
$SILO nice to see break .70
0 · Reply
dogood
dogood Jul. 16 at 10:34 PM
$SILO run like $ABVE
1 · Reply
psm18
psm18 Jul. 16 at 10:30 PM
$SILO only 7.21 million shares according to CNBC. This is about to go parabolic ! 💢🔥💯
1 · Reply
dogood
dogood Jul. 16 at 10:09 PM
$SILO can you run now
0 · Reply
dogood
dogood Jul. 16 at 9:53 PM
$SILO lets go
0 · Reply
BULLonROIDS
BULLonROIDS Jul. 16 at 7:36 PM
$SILO New publication in the Alzheimer's Research & Therapy journal about Silo Pharma drug candidate SPC-14 (ketamine + prucalopride) titled "Combinatorial targeting of NMDARs and 5-HT4Rs exerts beneficial effects in a mouse model of Alzheimer’s disease"
0 · Reply